1,307 reports of this reaction
2.7% of all PALIPERIDONE PALMITATE reports
#6 most reported adverse reaction
PRODUCT DOSE OMISSION ISSUE is the #6 most commonly reported adverse reaction for PALIPERIDONE PALMITATE, manufactured by Janssen Pharmaceuticals, Inc.. There are 1,307 FDA adverse event reports linking PALIPERIDONE PALMITATE to PRODUCT DOSE OMISSION ISSUE. This represents approximately 2.7% of all 48,953 adverse event reports for this drug.
PALIPERIDONE PALMITATE has an overall safety score of 85 out of 100. Patients taking PALIPERIDONE PALMITATE who experience product dose omission issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PRODUCT DOSE OMISSION ISSUE is a less commonly reported adverse event for PALIPERIDONE PALMITATE, but still significant enough to appear in the safety profile.
In addition to product dose omission issue, the following adverse reactions have been reported for PALIPERIDONE PALMITATE:
The following drugs have also been linked to product dose omission issue in FDA adverse event reports:
PRODUCT DOSE OMISSION ISSUE has been reported as an adverse event in 1,307 FDA reports for PALIPERIDONE PALMITATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PRODUCT DOSE OMISSION ISSUE accounts for approximately 2.7% of all adverse event reports for PALIPERIDONE PALMITATE, making it a notable side effect.
If you experience product dose omission issue while taking PALIPERIDONE PALMITATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.